✦ LIBER ✦

Non-A Non-B Hepatitis and the Safety of Intravenous Immune Globulin, pH 4.2: A Retrospective Survey:

✍ Scribed by Ralph H. Rousell; Robert A. Good; Bernard Pirofsky; Richard I. Schiff

Book ID: 115109270
Publisher: John Wiley and Sons
Year: 1988
Tongue: English
Weight: 688 KB
Volume: 54
Category: Article
ISSN: 0042-9007
DOI: 10.1111/j.1423-0410.1988.tb01605.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Transmission of Non-A, Non-B Hepatitis b

Transmission of Non-A, Non-B Hepatitis by pH4-Treated Intravenous Immunoglobulin

✍ Dr. P.E. Williams; P.L. Yap; J. Gillon; R.J. Crawford; S.J. Urbaniak; G. Galea 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 544 KB

Safety of Intravenous Immunoglobulin Pre

Safety of Intravenous Immunoglobulin Preparations: A Prospective Multicenter Study to Exclude the Risk of Non-A, Non-B Hepatitis

✍ Dr. P. Imbach; B.A. Perret; R. Babington; K. Kaminski; A. Morell; H.J. Heiniger 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 818 KB

Overview of the biochemistry and safety

Overview of the biochemistry and safety of a new native intravenous gamma globulin, IGIV, pH 4.25

✍ Richard S. Schwartz 📂 Article 📅 1987 🏛 Elsevier Science 🌐 English ⚖ 584 KB

High risk of non-A non-B hepatitis after

High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin

✍ P. B. A. Kernoff; C. A. Lee; P. Karayiannis; H. C. Thomas 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 645 KB

The three-year incidence of Non-B viral

The three-year incidence of Non-B viral hepatitis morbidity in a controlled trial of pre-exposure immune serum globulin prophylaxis

✍ J. D. Kark; E. Witztum; H. Mazkin; E. Nili; Y. L. Danon 📂 Article 📅 1984 🏛 Springer-Verlag 🌐 English ⚖ 660 KB

Inactivation of the Hutchinson strain of

Inactivation of the Hutchinson strain of hepatitis non-A, non-B virus in intravenous immunoglobulin by β-propiolactone

✍ Wolfgang Stephan; Herbert Dichtelmuller; Alfred M. Prince; Betsy Brotman; Teller 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 454 KB

beta-propiolactone (beta-PL) treatment has been evaluated for its ability to inactivate 10(3.5) chimpanzee infectious doses (CID50) of the Hutchinson strain of hepatitis non-A, non-B virus (HNANBV). Two chimpanzees were inoculated with a beta-PL-treated immunoglobulin solution to which this dose of